Title: Nemaura to Present Latest Developments at Maxim Group’s Emerging Growth in A.I. Conference
Nemaura (NASDAQ: NMRD), a leading medical technology company specializing in non-invasive wearable diagnostic devices and personalized lifestyle coaching programs, has announced that its CEO, Dr. Faz Chowdhury, will be unveiling new business updates and developments at the highly anticipated Maxim Group Emerging Growth in A.I. virtual conference. The presentation by Dr. Chowdhury is scheduled to commence at 11 a.m. ET on September 27, 2023. Interested individuals can register for the event by visiting the following link: [https://ibn.fm/nJxPW].
Nemaura is at the forefront of developing and commercializing non-invasive wearable diagnostic devices. The company is currently focused on the commercialization of its revolutionary products, sugarBEAT(R) and proBEAT(TM). sugarBEAT is a Class IIb medical device with a CE mark approval, offering individuals with diabetes and prediabetes real-time glucose measurements and essential insights derived from daily glucose trend data. This innovative device can assist in better managing, reversing, and preventing the onset of diabetes. Nemaura has also submitted a Premarket Approval Application (PMA) for sugarBEAT to the U.S. Food and Drug Administration (FDA). On the other hand, proBEAT combines non-invasive glucose data processed using artificial intelligence with a comprehensive lifestyle program designed for commercial launch.
Nemaura’s products cater to the tremendous potential in the global type 2 diabetes market, which is projected to reach an estimated value of nearly $59 billion by 2025. Additionally, the pre-diabetic market, valued at over $50 billion, presents a significant opportunity for the company. Moreover, Nemaura is poised to tap into the wearable health-tech sector, dedicated to weight loss and wellness applications, which is projected to reach a value of $60 billion by 2023.
With a distinctive focus on leveraging artificial intelligence and wearable technology, Nemaura is revolutionizing healthcare by providing individuals with innovative and personalized solutions to manage and prevent chronic diseases. The company’s commitment to developing groundbreaking products places them in a prime position within the rapidly evolving medical technology industry.
For more information about Nemaura and its cutting-edge solutions, please visit their official website at [www.NemauraMedical.com].
Note to Investors: Stay up to date with the latest news and updates regarding Nemaura by visiting their newsroom at [https://ibn.fm/NMRD].
About InvestorWire:
InvestorWire (IW) is a specialized communications platform that delivers advanced wire-grade press release syndication services to private and public companies, as well as the investment community. IW collaborates with more than 60 brands within the Dynamic Brand Portfolio @ IBN, offering access to a vast network of wire solutions that efficiently and effectively reach diverse industries, demographics, and target markets. With services ranging from article and editorial syndication to enhanced press release enhancement, social media distribution, and tailored corporate communications solutions, IW ensures maximum impact for its clients in a cluttered market. To learn more about InvestorWire and its unparalleled recognition and brand awareness services, please visit [https://www.InvestorWire.com].
Disclaimer: IW’s content, wherever published or re-published, is subject to the full terms of use and disclaimers available on the InvestorWire website at [https://www.InvestorWire.com/Disclaimer].
